Angiocrine Bioscience aims to transform medicine through the development of curative cellular therapies that restore, regenerate, and repair tissues and organs for patients with life-threatening and debilitating conditions, based on its proprietary, genetically engineered, E-CEL® technology platform.

We have a number of highly differentiated product candidates in our pipeline, with a focus on developing best-in-class cellular therapy products.

Hemato-Oncology Product Pipeline

Path to rapid development: ODD, RMAT, and/or Breakthrough Status
Product Target Indication Research Pre-clinical IND Enabling Phase I/II Phase II/III
AB-205 + HDT-ASCT1 Relapsed and/or Refractory Lymphoma

AB-205 + mdUCBT2 Life-threatening Leukemia & Myelodysplastic Syndrome

AB-245 Cancer/Autoimmune Disease Myeloablative HCT

AB-510 Aplastic Anemia

1 – HDT-ASCT: high dose chemotherapy and autologous stem cell transplantation is the standard of care for relapsed lymphoma
2 – mdUCBT: myeloablative allogeneic double unit umbilical cord blood transplantation is provided as curative therapy for patients with life-threatening leukemia & MDS who do not have an adult HLA-match stem cell source from relatives

ODD: Orphan Drug Designation eligible, RMAT: Regenerative Medicine Advanced Therapy designation eligible

Regenerative Medicine Product Pipeline

Path to rapid development: ODD, RMAT, and/or Breakthrough Status Eligible
Product Target Indication Research Pre-clinical IND Enabling Phase I/II Phase II/III
AB-205 Gel Matrix1 Arthroscopic Rotator Cuff Repair (RCR)

AB-205 Local Injection2 Outpatient Treatment of Fistula-in-Ano

AB-225 Spinal Cord Injury / Degenerative Disc Disease

AB-215 Post MI Recovery

AB-255 Severe COPD

1 – Single center IIT with Hospital for Special Surgery, New York
2 – Single center IIT with Weill Cornell Medicine, New York

ODD: Orphan Drug Designation eligible, RMAT: Regenerative Medicine Advanced Therapy designation eligible

AB-205 + HDT-ASCT

AB-205 is a novel, experimental, cellular therapy intended for treatment of toxicities related to high-dose chemotherapy with or without radiation. AB-205 is composed of endothelial cells genetically modified using the E-CEL® technology.

Clinical Study AB-205-001 (ongoing) is a first-in-human, open-label, non-randomized, safety study of AB-205 in patients with relapsed, chemo-sensitive, non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) who are undergoing high-dose therapy (HDT) and autologous stem cell transplantation (ASCT).

HDT-ASCT is a standard-of-care for relapsed lymphoma, including both NHL and HL. HDT involves the administration of high doses of multiple chemotherapies. In certain circumstances, oncologists prescribe local radiation in addition to HDT. HDT has been proven to be a very effective, curative therapy for high-risk, relapsed lymphoma. However, HDT also produced medically significant bystander effect, whereby multiple tissues and organs are affected, including the bone marrow; the gastrointestinal tract and oral mucosa; the lungs; the kidneys; and other healthy tissues. Following HDT, ASCT (autologous stem cell transplantation, using blood stem cells collected from the patient prior to administration of HDT) is performed to rescue the patient’s marrow and restore the blood and immune system. Because of the bystander effect which causes widespread damages to the vascular niche of multiple healthy tissues and organs, the main recovery mechanism (i.e., organ vascular niches) are disabled, leaving the patient to recovery slowly while experiencing serious side effects (prolonging hospital stay) and profound misery, affecting quality of life. Currently, there is no therapy that addresses the root of the slow recovery (i.e., damage to the vascular niches). Therefore, there is an immediate and substantial need for effective treatments that minimize the severe toxicities related to high-intensity cancer treatments.

AB-205 + HDT-ASCT is being studied in Clinical Study AB-205-001, partnered and co-funded by the California Institute of Regenerative Medicine (CIRM). This ongoing Phase 1 b trial has the following renowned clinical sites involved: Memorial Sloan Kettering Cancer Center (New York City, NY), City of Hope Cancer Center (Duarte, CA), MD Anderson Cancer Center (Houston, TX), Vanberbilt University Medical Center (Nashville, TN) and University of California Davis (Sacramento, CA).

For more information, please visit ClinicalTrials.gov

AB-205 + mdUCBT

Curative therapy mdUCBT or myeloablative allogeneic double unit umbilical cord blood transplantation is offered to patients with life-threatening leukemia & MDS who do not have an adult HLA-match stem cell source from relatives. AB-205 + mdUCBT combines the clinical proven stem cells from cord blood with AB-205, which is thought to act as chaperone cells that enable improved hematopoietic reconstitution (i.e., rebuilding of the blood and immune system) while decreasing ‘transplant-related’ complications and morbidities.

AB-205 + mdUCBT is being studied in Clinical Study AB-110-001, partnered and co-funded by the California Institute of Regenerative Medicine (CIRM). This ongoing Phase 1 b trial has the following renowned clinical sites involved: University of Colorado Anschutz Cancer Center (Denver, CO), City of Hope Cancer Center (Duarte, CA), and Memorial Sloan Kettering Cancer Center (New York City, NY).

For more information, please visit ClinicalTrials.gov

AB-205 Gel Matrix

AB-205 Gel Matrix can be directed to discrete locations to enhance the healing and repair of acute injuries.  Dr. Scott Rodeo, Attending Orthopedic Surgeon at Hospital for Special Surgery, Professor of Orthopedic Surgery at Weill Cornell Medical College and Head Team Physician for the New York Giants Football Team is leading this clinical trial.  In collaboration with Angiocrine Bioscience scientists he demonstrated that tendon repair could be enhanced. Full-thickness rotator cuff tears can often have slow healing with an incomplete functional recovery and even frequent re-tears.  The poor healing may be attributable to the poorly vascularized tendon tissue.  Complications are increasingly more frequent in patients of advanced age.

A first of its kind open-label, non-randomized, safety study trial repairing torn rotator cuffs will address the speed and strength of surgical repair enhanced with AB-205.  In order to maintain the AB-205 cells specifically at the site of surgical repair, the cells will be impregnated into a protein matrix.

For more information, please visit ClinicalTrials.gov

AB-205 Local Injection

AB-205 Local Injection will first be used in repairing anal fistulas.  These enfeebling abscesses are difficult to repair as the cleaned tissue is easily re-infected during the healing process.  Damage to the sphincter is also possible, creating life-long incontinence.  A robust and rapid healing of anal fistulas could lead to a reduction in fistula relapse and salvage of sphincter function.

An open-label, non-randomized, safety study trial repairing anal fistulas will attempt to achieve this goal of rapid and robust healing.  Dr. Jeffrey W. Milsom, Chief of Colon and Rectal Surgery and the Jerome J. Decossse, MD Professor of Surgery at New York Presbyterian/Weill Cornell Medical Center, is leading this trial in collaboration with Angiocrine.  AB-205 Local Injection will be locally administered during surgical repair of anal fistulas.  AB0-205 Local Injection has the potential to advance healing quickly enough to prevent relapse and prevent incontinence.

For more information, please visit ClinicalTrials.gov